Published on
July 14, 2014
- 17:16 GMT
Domainex Reports Success of its Lead Compound in Pre-clinical Model of COPD and Secures £1.4m Biomedical Catalyst Award
Domainex lead compound has demonstrated a more potent effect in a key model of chronic obstructive pulmonary disease than either roflumulast or a p38 inhibitor CAMBRIDGE, UK, July 9, 2014 /EINPresswire.com/ -- Domainex Ltd, a UK-based drug discovery …
Distribution channels:
Healthcare & Pharmaceuticals Industry
